盛德鑫泰(300881) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥520,798,083.74, representing a 66.44% increase year-over-year, and total revenue for the year-to-date is ¥1,238,464,971.10, up 39.59% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥21,015,169.68, a 13.82% increase year-over-year, with year-to-date net profit at ¥72,431,378.86, reflecting a 53.73% increase[5] - The company's basic and diluted earnings per share for Q3 2023 were both ¥0.19, up 5.56% from the same period last year, with year-to-date earnings per share at ¥0.66, an increase of 40.43%[5] - Total operating revenue for the third quarter of 2023 reached ¥1,238,464,971.10, an increase of 39.5% compared to ¥887,232,060.10 in the same period last year[21] - Net profit for the third quarter was ¥72,431,378.86, representing a 53.6% increase from ¥47,115,910.57 in the previous year[22] - The total comprehensive income for the period reached ¥72,431,378.86, compared to ¥47,115,910.57 in the previous period, reflecting a significant increase[23] - Basic and diluted earnings per share improved to ¥0.66 from ¥0.47 year-over-year[23] Assets and Liabilities - Total assets as of September 30, 2023, amounted to ¥2,039,720,408.67, a 27.81% increase from the end of the previous year[5] - Current assets totaled ¥1,541,971,610.23 as of September 30, 2023, compared to ¥1,274,340,768.96 at the beginning of the year, reflecting a growth of 20.9%[19] - The company's total assets increased to ¥2,039,720,408.67, up 27.8% from ¥1,595,951,273.03 at the start of the year[20] - Accounts receivable increased by 131.21% year-over-year to ¥500,544,935.83, primarily due to increased revenue from core business operations[9] - Accounts receivable rose significantly to ¥500,544,935.83, compared to ¥216,492,650.46 at the beginning of the year, marking an increase of 131.1%[19] - Inventory levels increased to ¥362,527,325.81, up from ¥280,323,593.54, indicating a growth of 29.3%[19] - Short-term borrowings increased to ¥243,834,317.69, compared to ¥154,863,587.12 at the beginning of the year, reflecting a rise of 57.4%[20] - The company's equity attributable to shareholders reached ¥875,404,148.66, an increase of 4.3% from ¥839,023,729.05 at the start of the year[20] Cash Flow - Cash flow from operating activities showed a net outflow of ¥19,299,970.24, an improvement of 93.64% compared to the previous year[11] - Cash inflows from operating activities totaled ¥1,120,082,727.59, up from ¥586,108,531.13 in the previous period[25] - The net cash flow from operating activities was -¥19,299,970.24, an improvement from -¥303,521,219.23 in the previous period[25] - Cash and cash equivalents at the end of the period decreased to ¥68,685,773.54 from ¥95,267,807.43 year-over-year[26] - Investment activities resulted in a net cash outflow of -¥202,675,368.34, compared to -¥103,203,715.62 in the previous period[25] - Financing activities generated a net cash inflow of ¥123,304,417.69, down from ¥303,496,260.04 in the previous period[25] - The company received ¥261,974,317.69 from borrowings, compared to ¥397,314,545.15 in the previous period[25] - The total cash outflow for operating activities was ¥1,139,382,697.83, compared to ¥889,629,750.36 in the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,473[12] - The top shareholder, Zhou Wenqing, holds 43.50% of the shares, totaling 47,850,000 shares[12] - The second-largest shareholder, Zong Huanqin, owns 20.25% of the shares, amounting to 22,275,000 shares[12] - The total number of restricted shares held by Zhou Wenqing is 35,887,500, with 11,962,500 shares released during the period[15] - The total number of restricted shares held by Zong Huanqin is 16,706,250, with 5,568,750 shares released during the period[15] - The combined total of restricted shares for both Zhou Wenqing and Zong Huanqin is 52,593,750 shares[15] Investments - The company reported a significant increase in long-term equity investments, which rose by 192.30% to ¥211,780,699.03, attributed to increased investment in Jiangsu Ruimei Automotive Parts Co., Ltd.[9] - The company has investments in various biotech firms, including a 0.3476% stake in Jiangsu Quanxin Biopharmaceutical Co., Ltd.[16] - The company also holds a 4.0839% stake in Shenzhen Hertz Life Science Technology Co., Ltd.[16] - The company has a 3.4109% stake in Suzhou Jiashu Medical Technology Co., Ltd.[16] Operating Costs - The company experienced a 40.19% increase in operating costs, totaling ¥1,073,949,405.83, due to expanded production capacity[10] - Total operating costs for the third quarter were ¥1,152,448,536.03, up 38.7% from ¥830,913,427.91 year-on-year[21] - Research and development expenses for the third quarter were ¥43,703,617.67, up from ¥34,818,312.79 in the same period last year, representing a growth of 25.5%[22] Other Income and Expenses - The financial expenses decreased by 58.16% to ¥2,408,682.29, resulting from lower short-term borrowing and discount rates[10] - The company reported a significant increase in other income, with a rise of 140018.62% to ¥28,065.76, attributed to increased insurance compensation[10] Audit Information - The company did not undergo an audit for the third quarter report[27]